



**BRET M. DICKEY, PH.D.**  
**CURRICULUM VITAE**

Executive Vice President  
Compass Lexecon  
1111 Broadway, Suite 1500  
Oakland, CA 94607  
(510) 285-1249  
[bdickey@compasslexecon.com](mailto:bdickey@compasslexecon.com)

**SUMMARY**

Bret Dickey is an Executive Vice President at Compass Lexecon and co-head of Compass Lexecon’s Oakland office. His fields of specialization include industrial organization, public economics, health economics, and econometrics and quantitative methods. He has nearly 25 years of experience in economic consulting, applying economic and quantitative analysis in the context of legal, regulatory, and policy disputes, particularly in the areas of antitrust, intellectual property, class certification, and damages. His research and consulting work have focused substantially on the healthcare and life sciences industries, particularly pharmaceuticals, but also health insurance, hospitals, medical devices, and laboratory and research equipment. His experience also spans a broad range of other industries including financial services, insurance, housing, technology, sports, and ticketing services. Dr. Dickey has testified in federal and state courts and before the U.S. House of Representatives. He serves on FTI Consulting’s Pro Bono Advisory Committee and has an active pro bono practice.

Dr. Dickey received an M.A. and a Ph.D. in Economics from Stanford University and a B.A. in Economics from the University of Pennsylvania. Prior to joining Compass Lexecon, he held positions at LECG, the SPHERE Institute, and the Council of Economic Advisers.

**EDUCATION**

Ph.D., Economics, STANFORD UNIVERSITY, Stanford, CA, 1999  
Fields of Specialization: Industrial Organization, Public Finance, Econometrics  
Dissertation: “Participation Dynamics in Low-Income Housing Assistance Programs”

M.A., Economics, STANFORD UNIVERSITY, Stanford, CA, 1995  
B.A., Economics (summa cum laude, with honors), UNIVERSITY OF PENNSYLVANIA, Philadelphia, PA, 1992

**PROFESSIONAL EXPERIENCE**

COMPASS LEXECON (formerly Competition Policy Associates), Oakland, CA, 2006 – present  
Executive Vice President  
Co-Head, Oakland Office  
Member, FTI Consulting Pro Bono Advisory Committee  
Senior Vice President (2007-2013), Vice President (2006-2007)

LECG, Emeryville, CA, 1999-2006

Principal

Senior Managing Economist (2003-2005), Managing Economist (2001-2002), Senior Economist (1999-2000)

STANFORD UNIVERSITY, Department of Economics, Stanford, CA, 1994-1997, 1999

Research Assistant

THE SPHERE INSTITUTE, Palo Alto, CA, 1997-1998

Research Associate

STANFORD UNIVERSITY, Department of Economics, Stanford, CA, 1997

Teaching Assistant, Introduction to Econometrics

AMERICAN ECONOMIC ASSOCIATION, Summer Minority Program, Stanford, CA, 1995

Teaching Assistant, Applied Microeconomic Analysis and Introduction to Econometrics

COUNCIL OF ECONOMIC ADVISERS, Executive Office of the President, Washington, DC, 1992-1993

Research Assistant

## **PUBLICATIONS**

“Monopoly” (with Daniel L. Rubinfeld) in the *Elgar Encyclopedia on the Economics of Competition, Regulation and Antitrust*, Michael D. Noel (Editor). Cheltenham, UK: Edward Elgar Publishing (forthcoming).

“Monopolization” (with Daniel L. Rubinfeld) in the *Elgar Encyclopedia on the Economics of Competition, Regulation and Antitrust*, Michael D. Noel (Editor). Cheltenham, UK: Edward Elgar Publishing (forthcoming).

“Pharmaceutical Product Hopping: Is There a Role for Antitrust Scrutiny?” (with Kun Huang and Daniel L. Rubinfeld), *Antitrust Law Journal*, Vol. 82, Issue 2, 2019, pp. 679-699.

“Would the *Per Se* Illegal Treatment of Reverse Payment Settlements Inhibit Generic Drug Investment?” (with Daniel L. Rubinfeld), *Journal of Competition Law & Economics*, Vol. 8, Issue 3, 2012, pp. 615-625.

“Antitrust Class Certification: Towards an Economic Framework” (with Daniel L. Rubinfeld), *New York University Annual Survey of American Law* (part of symposium on Critical Directions in Antitrust), Vol. 66, Issue 3, 2011, pp. 459-486.

“An Economic Assessment of Patent Settlements in the Pharmaceutical Industry” (with Jonathan Orszag and Laura Tyson), *Annals of Health Law*, Vol. 19, Issue 2, Winter 2010, pp. 367-400.

“Patent Settlements in the Pharmaceutical Industry: Balancing Intellectual Property and Antitrust Concerns” (with Kelly Lear Nordby), *Trade Practices Law Journal*, Vol. 12, No. 3, September 2004, pp. 175-180.

“*De Facto* Exclusive Dealing and the *Concord Boat Case*” (with Michael P. Akemann), *Trade Practices Law Journal*, December 2001, pp. 281-286.

## **INVITED TESTIMONY AND PRESENTATIONS**

Compass Lexecon, China Summit, “Antitrust/IP Developments in the Pharmaceutical

Industry,” April 21, 2024.

American Bar Association, Pricing Conduct and Health Care and Pharmaceuticals Committees, “Pharmaceutical Product Hopping: What is the Role for Antitrust Enforcement?” February 25, 2020.

Los Angeles County Bar Association, Antitrust and Unfair Business Practices Section, “Beyond *FTC v. Actavis*: Recent and Emerging Issues at the Intersection of Antitrust and the Pharmaceutical Industry,” May 29, 2015.

Duke Law School, “New Approaches and Incentives in Drug Development,” November 22, 2013.

U.S. House of Representatives, Committee on the Judiciary, Subcommittee on Courts and Competition Policy, Hearing on “Pay to Delay: Are Patent Settlements that Delay Generic Drug Market Entry Anticompetitive?” June 3, 2009.

## **HONORS AND AWARDS**

Lawyers’ Committee for Civil Rights of the San Francisco Bay Area, Robert G. Sproul, Jr. Award (for pro bono work), 2017

Stanford University, Center for Economic Policy Research, Olin Foundation Dissertation Fellowship, 1997-1998

Stanford University, Department of Economics, Outstanding Teaching Assistant Award (Honorable Mention), 1997

Stanford University, Graduate Fellowship, 1993-1994

Phi Beta Kappa, 1992

## **PROFESSIONAL AFFILIATIONS**

American Economic Association

American Society of Health Economists

American Bar Association (Associate)